# US 2016/0354472 A1 · Use of human serum albumin to decrease antigenicity of therapeutic proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354472 A1
- Document ID: US20160354472A1
- Status: Published application
- Kind: A1
- Application number: 13/280,165
- Filed: 2011-10-24
- Published: 2016-12-08
- Earliest claimed: 2010-10-22
- Assignees: Protox Therapeutics, Inc.
- Inventors: Fahar Merchant
- Web page: https://patentgrep.com/patent/US20160354472A1

## CPC

- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/164: {from bacteria}
- A61K 38/2026: {IL-4}
- A61K 38/385: {Serum albumin}
- A61K 47/02: Inorganic compounds
- A61P 35/00: Antineoplastic agents
- C07K 16/12: against material from bacteria
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are therapeutic compositions that include albumin (such as human serum albumin) and therapeutic proteins, such as a modified proaerolysin protein or an apoptosis-modulating fusion protein, as well as kits that include such compositions in containers. Also provided are methods of using such compositions in decreasing the antigenicity of therapeutic proteins such as modified proaerolysin proteins or apoptosis-modulating fusion protein antibodies (for example as evidenced by a decrease in the production of neutralizing antibodies).

## Claims

### Claim 1

A pharmaceutical composition, comprising:
albumin; and
a modified proaerolysin protein, wherein the modified proaerolysin protein comprises a prostate-specific protease cleavage site that replaces a proaerolysin furin cleavage site corresponding to amino acids 427-432 of SEQ ID NO: 2.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said albumin is human serum albumin.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the albumin is a recombinant human serum albumin or a human serum albumin purified from human blood.

### Claim 4 (depends on 2)

The composition of claim 2, wherein said therapeutic protein is a modified proaerolysin protein selected from SEQ ID NO: 4 and SEQ ID NO: 28.

### Claim 5 (depends on 4)

The composition of claim 4, wherein said therapeutic protein is the protein of SEQ ID NO: 4.

### Claim 6 (depends on 4)

The composition of claim 4, wherein said therapeutic protein is the protein of SEQ ID NO: 28.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the molar ratio of the amount of human serum albumin to the amount of therapeutic protein is between 5:1 and 100,000:1.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the molar ratio of the amount of human serum albumin to the amount of therapeutic protein is between 50:1 and 5,000:1.

### Claim 9 (depends on 6)

The composition of claim 6, wherein the amount of human serum albumin in the pharmaceutical composition is between 0.01 and 25% by weight.

### Claim 10 (depends on 7)

The composition of claim 7, wherein the amount of human serum albumin in the pharmaceutical composition is between 0.2 and 5% by weight.

### Claim 11 (depends on 8)

The composition of claim 8, wherein the amount of human serum albumin in the pharmaceutical composition is between 1.8 and 2.2% by weight.

### Claim 12 (depends on 9)

The composition of claim 9, wherein the amount of human serum albumin in the pharmaceutical composition is about 2% by weight.

### Claim 13 (depends on 6)

The composition of claim 6, wherein the amount of the protein of SEQ ID NO: 28 is between 2 and 4 μg/ml.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the amount of the protein of SEQ ID NO: 28 is between 2.5 and 3.5 μg/ml.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the amount of the protein of SEQ ID NO: 28 is between 2.8 and 3.2 μg/ml.

### Claim 16 (depends on 15)

The composition of claim 15, wherein the amount of the protein of SEQ ID NO: 28 is about 3 μg/ml.

### Claim 17 (depends on 16)

The composition of claim 16, wherein the amount of human serum albumin in the pharmaceutical composition is about 2% by weight.

### Claim 18 (depends on 17)

The composition of claim 17, comprising an aqueous solution of:
between 0.05 and 25.0 μg/ml of the protein of SEQ ID NO: 28;
between 1.5 and 2.5% human serum albumin by weight;
between 100 and 200 mM NaCl;
between 0.1 and 1.0 mM NaH2PO4;
between 5 and 15 mM Na2HPO4; and
between 0.5 and 1.5 mM disodium ethylenediaminetetraacetic acid.

### Claim 19 (depends on 18)

The composition of claim 18, comprising:
between 0.5 and 10.0 μg/ml of the protein of SEQ ID NO: 28;
between 1.8 and 2.2% human serum albumin by weight;
between 130 and 140 mM NaCl;
between 0.5 and 0.7 mM NaH2PO4;
between 7 and 9 mM Na2HPO4; and
between 0.8 and 1.0 mM disodium ethylenediaminetetraacetic acid.

### Claim 20 (depends on 18)

The composition of claim 18, comprising:
between 0.5 and 10.0 μg/ml of the protein of SEQ ID NO: 28;
about 2% human serum albumin by weight;
about 138 mM NaCl;
about 0.6 mM NaH2PO4;
about 8.5 mM Na2HPO4; and
about 0.92 mM disodium ethylenediaminetetraacetic acid.

### Claim 21

A kit, comprising:
a first container containing the therapeutic protein of SEQ ID NO: 28; and
a second container containing human serum albumin.

### Claim 22 (depends on 21)

The kit of claim 21, wherein
the first container contains a solution comprising about 300 μg/ml of the therapeutic protein of SEQ ID NO: 28;
the second container contains a solution comprising about 2% human serum albumin; and
further comprising instructions to transfer the solution from the first container into the second container.

### Claim 23 (depends on 22)

The kit of claim 22, wherein the second container contains a solution comprising:
between 0.5 and 10.0 μg/ml of the protein of SEQ ID NO: 28;
between 1.8 and 2.2% human serum albumin by weight;
between 130 and 140 mM NaCl;
between 0.5 and 0.7 mM NaH2PO4;
between 7 and 9 mM Na2HPO4; and
between 0.8 and 1.0 mM disodium ethylenediaminetetraacetic acid.

### Claim 24 (depends on 23)

The kit of claim 23, wherein the second container contains a solution comprising:
between 0.5 and 10.0 μg/ml of the protein of SEQ ID NO: 28;
about 2% human serum albumin by weight;
about 138 mM NaCl;
about 0.6 mM NaH2PO4;
about 8.5 mM Na2HPO4; and
about 0.92 mM disodium ethylenediaminetetraacetic acid.

### Claim 25 (depends on 4)

A method for treating benign prostatic hyperplasia in a subject comprising the administration of a therapeutically effective amount of the composition of claim 4 to a patient in need thereof.

### Claim 26 (depends on 25)

The method of claim 25, wherein administration of the composition results in a reduction in prostate volume or weight or a reduction in the rate of prostate growth.

### Claim 27 (depends on 26)

The method of claim 26, wherein the prostate size is reduced by at least 10%.

### Claim 28 (depends on 25)

The method of claim 25, wherein the composition is administered intraprostatically.

### Claim 29 (depends on 28)

The method of claim 28, wherein the amount of the protein of SEQ ID NO: 28 which exits from the prostate after administration is reduced in comparison with a composition which does not comprise human serum albumin.

### Claim 30 (depends on 29)

The method of claim 29, wherein the amount of the protein of SEQ ID NO: 28 which exits from the prostate after administration is reduced by at least 1%, at least 2%, at least 5%, at least 10%, at least 15%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.

### Claim 31 (depends on 25)

The method of claim 25, wherein the immune response is decreased in comparison with a composition which does not comprise human serum albumin.

### Claim 32 (depends on 31)

The method of claim 31, wherein the immune response is an antibody response.

### Claim 33 (depends on 32)

The method of claim 32, wherein the antibody response is decreased by at least 1%, at least 2%, at least 5%, at least 10%, at least 15%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.

### Claim 34 (depends on 33)

The method of claim 33, wherein the antibody response is decreased by at least 90%.

### Claim 35 (depends on 33)

The method of claim 33, wherein the antibody response is decreased 2-fold to 10-fold.

### Claim 36 (depends on 4)

A method for treating prostate cancer in a subject comprising the administration of a therapeutically effective amount of the composition of claim 4 to a patient in need thereof.

### Claim 37 (depends on 36)

The method of claim 36, wherein the subject has a localized prostate tumor.

### Claim 38 (depends on 36)

The method of claim 36, wherein the subject has metastatic prostate cancer.

### Claim 39 (depends on 36)

The method of claim 36, wherein administration of the composition results in a reduction in prostate tumor volume.

### Claim 40 (depends on 39)

The method of claim 39, wherein the prostate tumor volume is reduced by at least 10%.

### Claim 41 (depends on 36)

The method of claim 36, wherein the composition is administered intraprostatically.

### Claim 42 (depends on 41)

The method of claim 41, wherein the amount of the protein of SEQ ID NO: 28 which flows out from the needle and prostate in conjunction with administration is reduced in comparison with a composition which does not comprise human serum albumin.

### Claim 43 (depends on 42)

The method of claim 42, wherein the amount of the protein of SEQ ID NO: 28 which flows out from the needle and prostate in conjunction with administration is reduced by at least 1%, at least 2%, at least 5%, at least 10%, at least 15%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.

### Claim 44 (depends on 36)

The method of claim 36, wherein the immune response is decreased in comparison with a composition which does not comprise human serum albumin.

### Claim 45 (depends on 44)

The method of claim 44, wherein the immune response is an antibody response.

### Claim 46 (depends on 45)

The method of claim 45, wherein the antibody response is decreased by at least 1%, at least 2%, at least 5%, at least 10%, at least 15%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.

### Claim 47 (depends on 46)

The method of claim 46, wherein the antibody response is decreased by at least 90%.

### Claim 48 (depends on 45)

The method of claim 45, wherein the antibody response is decreased 2-fold to 10-fold.

### Claim 49

A method of decreasing an antibody response to a therapeutic protein of selected from SEQ ID NO: 4 and SEQ ID NO: 28 comprising administering the therapeutic protein to the subject in a pharmaceutical composition comprising a sufficient amount of albumin to decrease the subject's antibody response to the therapeutic protein.

### Claim 50 (depends on 49)

The method of claim 49, wherein the antibody response is decreased by 10% to 90%.

### Claim 51 (depends on 50)

The method of claim 50, wherein the antibody response is decreased by at least 90%.

### Claim 52 (depends on 49)

The method of claim 49, wherein the antibody response is decreased 2-fold to 10-fold.

### Claim 53 (depends on 49)

The method of claim 49, wherein the albumin is a human serum albumin.

### Claim 54 (depends on 53)

The method of claim 53, wherein the albumin is a recombinant human serum albumin or a human serum albumin purified from human blood.

### Claim 55 (depends on 49)

The method of claim 49, wherein the molar ratio of the amount of albumin to the amount of therapeutic protein is between 5:1 and 100,000:1 or between 50:1 and 5,000:1.

### Claim 56 (depends on 49)

The method of claim 49, wherein the amount of albumin in the pharmaceutical composition is between 0.01 and 25% by weight, between 0.2 and 5% by weight, or 2% by weight.

### Claim 57

A method of decreasing an antibody response to a therapeutic protein in a subject in need of treatment therewith, comprising administering the therapeutic protein to the subject in a pharmaceutical composition comprising a sufficient amount of albumin to decrease the subject's antibody response to the therapeutic protein.

### Claim 58 (depends on 57)

The method of claim 57, wherein the antibody response is decreased by 10% to 90%.

### Claim 59 (depends on 58)

The method of claim 58, wherein the antibody response is decreased by at least 90%.

### Claim 60 (depends on 57)

The method of claim 57, wherein the antibody response is decreased 2-fold to 10-fold.

### Claim 61 (depends on 57)

The method of claim 57, wherein the albumin is a human serum albumin.

### Claim 62 (depends on 61)

The method of claim 61, wherein the albumin is a recombinant human serum albumin or a human serum albumin purified from human blood.

### Claim 63 (depends on 61)

The method of claim 61, wherein the molar ratio of the amount of albumin to the amount of therapeutic protein is between 5:1 and 100,000:1 or between 50:1 and 5,000:1.

### Claim 64 (depends on 61)

The method of claim 61, wherein the amount of albumin in the pharmaceutical composition is between 0.01 and 25% by weight, between 0.2 and 5% by weight, or 2% by weight.

### Claim 65 (depends on 61)

The method of claim 61, wherein the therapeutic protein is a targeted cargo protein, wherein the targeted cargo protein comprises:
a targeting moiety that specifically binds to a target displayed by a target cell, and
a cargo moiety that exerts a biological effect on the target cell.

### Claim 66 (depends on 65)

The method of claim 65, wherein the targeted cargo protein comprises one or more cargo moieties selected from aerolysin, proaerolysin, bouganin, abrin, ricin, Pseudomonas exotoxin, cholera toxin, diphtheria toxin, tetanus toxin, neural thread protein and Bad.

### Claim 67 (depends on 65)

The method of claim 65, wherein the target is a receptor for IL-2, IL-4, IL-13, GM-CSF, EGF, proaerolysin toxin, diphtheria toxin, anthrax toxin and tetanus toxin.

### Claim 68 (depends on 65)

The method of claim 65, wherein the targeting moiety comprises a ligand for a receptor for IL-2, IL-4, IL-13, GM-CSF, EGF, nicotinic acetylcholine, CD22 or GPI anchor protein.

### Claim 69 (depends on 65)

The method of claim 65, wherein the targeted cargo protein comprises Pseudomonas exotoxin linked to circularly permuted IL-4, IL-2 linked to aerolysin, IL-2 linked to proaerolysin, IL4 linked to BAD, GMCSF linked to BAD, EGF linked to proaerolysin, anti-EpCAM antibody linked to Pseudomonas exotoxin, anti-EpCAM antibody linked to bouganin, anti-mesothelin antibody linked to Pseudomonas exotoxin, anti-CD22 antibody linked to Pseudomonas exotoxin, anti-CD22 antibody linked to RNase A, and anti-PSMA antibody linked to thapsigargin.

### Claim 70 (depends on 69)

The method of claim 69, wherein the therapeutic protein comprises Pseudomonas exotoxin linked to circularly permuted IL-4 and the molar ratio of the amount of the therapeutic protein to the amount of albumin is 5:1 to 5000:1, such as 50:1.

### Claim 71 (depends on 61)

The method of claim 61, wherein the therapeutic protein comprises an apoptosis-modifying fusion protein comprising an inactive toxin protein domain, an apoptosis regulating protein domain, wherein the inactive toxin protein domain targets the fusion protein to the cell and is not biologically active.

### Claim 72 (depends on 71)

The method of claim 71, wherein the apoptosis regulating protein domain comprises a Bcl-2 protein.

### Claim 73 (depends on 72)

The method of claim 72, wherein the Bcl-2 protein is a pro-apoptotic protein selected from Bcl-xs, Bax, Bad, Bak, DIVA, Bak, Bik, Bim, Bid and Egl-1, or an anti-apoptotic protein selected from Bcl-xL, Mcl-1, Ced-9 and A1.

### Claim 74 (depends on 72)

The method of claim 72, wherein the inactive toxin protein domain comprises a domain derived from diphtheria toxin, tetanus toxin or anthrax toxin.

### Claim 75

A pharmaceutical composition comprising:
albumin; and
a therapeutic protein selected from the group consisting of:
an apoptosis-modifying fusion protein comprising an inactive toxin protein domain and an apoptosis regulating protein domain, wherein the inactive toxin protein domain targets the fusion protein to the cell and is not biologically active, or
a targeted cargo protein, comprising a targeting moiety that specifically binds to a target displayed by a target cell, and a cargo moiety that exerts a biological effect on a target cell.

### Claim 76 (depends on 75)

The composition of claim 75, wherein the albumin is human serum albumin.

### Claim 77 (depends on 76)

The composition of claim 76, wherein the apoptosis regulating protein domain comprises a Bcl-2 protein domain.

### Claim 78 (depends on 77)

The composition of claim 77, wherein the Bcl-2 protein is Bcl-XL.

### Claim 79 (depends on 78)

The composition of claim 78, wherein the Bcl-XL comprises amino acid residues 1-209 of Bcl-XL.

### Claim 80 (depends on 76)

The composition of claim 76, wherein the inactive toxin protein domain comprises an inactive anthrax toxin domain or an inactive diphtheria toxin domain.

### Claim 81 (depends on 80)

The composition of claim 80, wherein the inactive anthrax toxin domain comprises an amino terminal portion of mature anthrax lethal factor (LF).

### Claim 82 (depends on 81)

The composition of claim 81, wherein the amino terminal portion comprises amino acid residues 1-255 of mature anthrax LF.

### Claim 83 (depends on 76)

The composition of claim 76, wherein the therapeutic protein comprises at least 95% sequence identity to the amino acid sequence shown in SEQ ID NO: 26.

### Claim 84 (depends on 80)

The composition of claim 80, wherein the inactive diphtheria toxin domain comprises the translocation region (domain or sub-domain) of diphtheria toxin.

### Claim 85 (depends on 77)

The composition of claim 77, wherein the therapeutic protein comprises at least 95% sequence identity to the amino acid sequence shown in SEQ ID NO: 20 or 22.

### Claim 86 (depends on 75)

A method for modifying apoptosis in a target cell, comprising contacting the target cell with an amount of the composition of claim 75, sufficient to inhibit apoptosis.

### Claim 87 (depends on 86)

The method of claim 86, wherein apoptosis in the target cell is inhibited.

### Claim 88 (depends on 87)

The method of claim 87, wherein the target cell is a neuron, a lymphocyte, a macrophage, an epithelial cell, or a stem cell.

### Claim 89 (depends on 86)

The method of claim 86, wherein apoptosis in the target cell is enhanced.

### Claim 90 (depends on 89)

The method of claim 89, further comprising the step of co-administering an agent selected from the group consisting of a chemotherapeutic agent, an anti-inflammatory agent, an anti-viral agent, and an antibiotic agent.

### Claim 91 (depends on 89)

The protein of claim 89, wherein the target cell is a tumor cell, a cancer cell, a neoplasm cell, a hyper-proliferative cell, or an adipocyte.

### Claim 92 (depends on 75)

A method of reducing apoptosis in a subject after transient ischemic neuronal injury, comprising administering to the subject a therapeutically effective amount of the composition of claim 75.

### Claim 93 (depends on 92)

The method of claim 92, wherein the transient ischemic neuronal injury is a spinal cord injury.
